FDA initiatives aimed at standardizing and better integrating Risk Evaluation and Mitigation Strategies into the health care system could provide the agency with an opportunity to address challenges that have arisen in the development of single REMS programs shared by multiple sponsors.
For the pharmaceutical industry, greater standardization and integration of risk management programs into the health care delivery system is likely to require better coordination and cooperation among drug sponsors
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?